Elsevier

The Lancet

Volume 344, Issue 8933, 12 November 1994, Pages 1323-1328
The Lancet

Articles
Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans

https://doi.org/10.1016/S0140-6736(94)90693-9Get rights and content

Abstract

Summary

Among HIV-positive patients who received treatment for active tuberculosis, thiacetazone has been associated with cutaneous hypersensitivity and recurrent tuberculosis. No controlled trials have investigated the safety and efficacy of thiacetazone-containing regimens compared with alternative regimens among patients with HIV. In a randomised clinical trial of 191 HIV-positive patients with active pulmonary tuberculosis, we examined the safety and short-term efficacy of isoniazid, rifampicin, and pyrazinamide for two months followed by isoniazid and rifampicin for seven months (RHZ) compared with streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for ten months (STH). Between May, 1990, and September, 1991, 191 HIV-positive adult Ugandan patients with acid-fast bacilli sputum smear-positive pulmonary tuberculosis (93% confirmed by culture) received either STH or RHZ. Subjects had a standard evaluation that included Mantoux skin test, complete blood count with differential white blood cell count, and chest radiography. After starting therapy, subjects were followed-up over one year for three outcomes: complications of anti-tuberculosis therapy, early sterilisation of cultures, and survival. Of 191 eligible subjects, 90 received STH and 101 received RHZ. The overall one-year survival was similar for STH and RHZ (65% vs 72%), but when controlled for baseline differences in Mantoux reaction size and absolute lymphocyte count, the relative risk of death for STH compared with RHZ was 1·57 (95% Cl 1·0-2·48). Overall, 12 adverse drug reactions occurred in the STH arm (18·2 reactions per 100 person years [PYO]) compared with one in the RHZ arm (1·6 reactions per 100 PYO) for a relative risk of 11·7 (95% Cl 1·52-90·0). 10 cutaneous reactions occurred in the STH arm (15·2 events per 100 PYO) compared with one event in the RHZ arm (1·6 events per 100 PYO) for a relative risk of 9·7 (95% Cl: 1·24, 75·8). A greater proportion of RHZ patients compared with STH patients had sterilised their sputum within two months (74% vs 37%, p<0·001).

In developing countries, rifampicin-containing regimens should be given, when possible, to HIV-positive patients to reduce drug toxicity and to prolong survival.

References (29)

  • Pm Small et al.

    Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection

    N Engl J Med

    (1991)
  • Ry Keers

    Pulmonary Tuberculosis. A Journey Down the Centuries

    (1978)
  • Ab Miller et al.

    An international co-operative investigation into thiacetazone (thioacetazone*) side-effects

    Tubercle

    (1966)
  • Gc Ferguson et al.

    A second international co-operative investigation into thiacetazone side-effects

    Tubercle

    (1971)
  • Cited by (110)

    • Multi-drug resistant Mycobacterium tuberculosis &amp; oxidative stress complexity: Emerging need for novel drug delivery approaches

      2018, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Such systems can not only improve the patient compliance but also minimize the risk of toxicity and other unwanted effects associated with the chemotherapy treatment. Various controlled drug delivery systems include microspheres, polymeric nanoparticles, liposomes, niosomes, liquid crystals, solid lipid nanoparticles, polymeric micelles, dendrimers, nanoemulsion, nanosuspension, silica nanoparticles, and microparticles [2–6,13–18]. Table 1 represents the opportunities of nano drug delivery over the conventional approach for the treatment of tuberculosis.

    • Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: A systematic review and meta-analysis

      2014, International Journal of Infectious Diseases
      Citation Excerpt :

      The overall rates of favorable response to ATT were comparable between studies, with no significant differences between groups. A rifampin-containing regimen has been recommended by the WHO for the treatment of TB in patients infected with HIV due to its more favorable outcomes than non-rifampin treatments.33 ART is also important for the treatment of TB, as viral suppression is necessary for the restoration of Mycobacterium tuberculosis-specific CD4+ T cell responses.34

    • Paediatric use of second-line anti-tuberculosis agents: A review

      2012, Tuberculosis
      Citation Excerpt :

      Thiacetazone was used widely to treat TB prior to the advent of HIV. Severe, life-threatening Stevens Johnson reactions were associated with thiacetazone use in HIV-infected adults186,187 and children.188 Although it is contraindicated only in HIV-infected individuals, it is now rarely available in most countries.

    • Tuberculosis and Atypical Mycobacterial Infections

      2011, Tropical Infectious Diseases: Principles, Pathogens and Practice
    • Tuberculosis and Atypical Mycobacterial Infections

      2011, Tropical Infectious Diseases
    • Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: A four-year prospective study

      2010, International Journal of Infectious Diseases
      Citation Excerpt :

      Although rifabutin has fewer problematic drug–drug interactions, it is not available in many countries, particularly not in resource-limited settings. However, rifamycin-containing regimens are preferred in the treatment of HIV and TB co-infection as they result in a lower relapse rate and better outcome.7 According to current HIV treatment guidelines, including Thai guidelines, efavirenz-based ART is a preferred first-line regimen in HIV/TB co-infected patients who are receiving a rifampin-containing regimen, because of the lesser drug–drug interactions when compared to nevirapine or PIs.8

    View all citing articles on Scopus
    1

    Participants are listed at the end of the article.

    View full text